By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Can-Fite BioPharma Ltd. 

Reinhold Cohn House
P.O.Box: 4060
Tel Aviv      Israel
Phone: 03-7109330 Fax: 03-5606405


Drug Discovery

Company News
Can-Fite BioPharma (CFBI) Files Clinical Trial Application In Canada For Piclidenoson Ahead Of Upcoming Acrobat Rheumatoid Arthritis Phase III Study 5/16/2017 7:24:33 AM
Can-Fite BioPharma (CFBI)'s Liver Protective Drug Namodenoson Enters Phase II Trial For Treatment Of NAFLD/NASH 5/3/2017 7:32:04 AM
Can-Fite BioPharma (CFBI)'s Phase III ACRobat Trial In Rheumatoid Arthritis Approved By Institutional Review Board 4/25/2017 6:27:02 AM
Can-Fite BioPharma (CFBI) Reports 2016 Financial Results & Provides Clinical Update 3/31/2017 9:08:55 AM
New Preclinical Data Show Can-Fite BioPharma (CFBI)'s Namodenoson (CF102) Prevents Progression Of Liver Fibrosis 2/28/2017 6:41:17 AM
Can-Fite BioPharma (CFBI) Gears Up For ACRobat, Its Phase III Trial Of Piclidenoson In Rheumatoid Arthritis 2/8/2017 7:04:09 AM
Can-Fite BioPharma (CFBI) Release: Company Announces $5 Million Registered Direct Offering 1/19/2017 8:11:43 AM
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017 7:33:28 AM
Can-Fite BioPharma (CFBI) Receives $500,000 Payment As Part Of $3 Million Distribution Deal For Liver Cancer Drug Namodenoson (CF102) In South Korea 12/21/2016 12:28:34 PM
New Preclinical Data Show Can-Fite BioPharma (CFBI)'s Namodenoson (CF102) Inhibits Liver Fibrosis -- Supports Potential Efficacy In Treatment Of NASH 12/16/2016 9:22:11 AM